Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030

Immuno-Oncology Innovation and R&D Investment Accelerate Growth

Apr. 10, 2026 at 12:40pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life photograph showing a polished glass vial filled with a glowing blue liquid, representing the advanced technology behind bispecific antibodies. The vial is elegantly arranged on a clean, white background, using dramatic lighting to convey a sense of scientific precision and innovation.Bispecific antibodies, a rapidly evolving class of targeted cancer therapies, are driving innovation and investment in the global immuno-oncology market.Boston Today

The global bispecific antibodies market is projected to grow from $12.9 billion in 2024 to $22.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.7%, according to a new report from BCC Research. The report cites the rising global burden of cancer, accelerating R&D investment by major pharmaceutical and biotechnology companies, and the growing adoption of immuno-oncology therapies as key drivers of this market expansion.

Why it matters

Bispecific antibodies offer unique mechanisms of action, including T-cell redirection and dual-antigen targeting, that address limitations of conventional monoclonal antibodies. The growing adoption of immuno-oncology in standard treatment pathways is expanding the addressable market, and the development of bispecific approaches for solid tumors represents a significant growth frontier.

The details

North America leads the global bispecific antibodies market with 33.1% market share, reflecting the region's concentration of biopharmaceutical R&D, advanced clinical trial infrastructure, early regulatory approvals and strong payer coverage for novel oncology therapeutics. Next-generation bispecific formats are advancing rapidly, including formats with improved stability and half-life, subcutaneous and outpatient-optimized formulations, AI-assisted antibody design and target selection, combination regimens with immune checkpoint inhibitors, and conditional activation and tumor-restricted bispecific designs.

  • The global bispecific antibodies market will reach $22.3 billion by 2030.
  • The market is growing at a 9.7% compound annual growth rate (CAGR) from a 2024 base of $12.9 billion.

The players

BCC Research

A market research firm that provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports.

AbbVie

A major pharmaceutical company that is part of the competitive landscape in the bispecific antibodies market.

Amgen

A major biotechnology company that is part of the competitive landscape in the bispecific antibodies market.

AstraZeneca

A major pharmaceutical company that is part of the competitive landscape in the bispecific antibodies market.

Bristol-Myers Squibb

A major pharmaceutical company that is part of the competitive landscape in the bispecific antibodies market.

F. Hoffmann-La Roche

A major pharmaceutical company that is part of the competitive landscape in the bispecific antibodies market.

Got photos? Submit your photos here. ›

The takeaway

The bispecific antibodies market is being propelled by several converging forces, including the rising global burden of cancer, accelerating R&D investment by major pharmaceutical and biotechnology companies, and the growing adoption of immuno-oncology therapies in standard treatment pathways. Companies with diversified bispecific portfolios, subcutaneous formulations, and AI-integrated discovery platforms are best positioned for long-term value creation in this rapidly evolving market.